News | November 01, 2022
Aptar Pharma completes Phase I global injectables expansion program
The expansion program includes investments in France and the U.S., adding an additional 23,000+ m² of manufacturing footprint.
The expansion program includes investments in France and the U.S., adding an additional 23,000+ m² of manufacturing footprint.
This is the first injectable product approval from our General Sterile Facility (F-3) which was inspected in August, 2022.
Acetaminophen injection had annual sales of US $72 million in the United States according to IQVIA data
Micafungin for Injection had annual sales of US $99 million in the United States according to IQVIA data
Sugammadex is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults undergoing surgery
The integrated capabilities at Unit 2 offer significant operational flexibility, greater efficiency, and varied scope within the same premise
Formoterol Fumarate Inhalation Solution (RLD Perforomist) had estimated annual sales of US $282 million in the US
The approved product has an estimated market size of around US $62 million for the twelve months ending June 2022 according to IQVIA
According to industry sales data, Yondelis generated annual sales of $49.7 million for the twelve months ending June 2022 in the US market.
The approved product has an estimated market size of around US$ 606 million for the twelve months ending June 2022, according to IQVIA.
Subscribe To Our Newsletter & Stay Updated
